Retransmission of the press release that was published, with the associated MAR label, on August 31, 2023, at 17:35 CET.
AcuCort AB has today signed a partnership agreement for Sweden, Norway, Denmark and Finland with Unimedic Pharma. The agreement means that Unimedic will be responsible for sales and marketing of AcuCort’s oral film Zeqmelit® in these countries.
With the agreement, AcuCort enters the commercialization phase that the company has been preparing for a long time. Previously, the company's oral film Zeqmelit® has received approval from pharmaceutical authorities in Sweden, Denmark, Norway and Finland, which allows for a commercial venture in these countries.
"The agreement with Unimedic Pharma is important for our success in the Nordic markets. Unimedic Pharma is a very reputable company with specialist expertise in the sales and marketing of pharmaceuticals in the Nordics, which we now benefit from as AcuCort enters a new chapter on its growth journey ", says AcuCort´s CEO Jonas Jönmark.
Unimedic Pharma's CEO Johan Frödin says in a comment:
"We have followed AcuCort for a long time and have been impressed by the innovative power that exists in the company. Zeqmelit is a product that fits well into our range and contributes to our vision of enabling a better life. We look forward to the collaboration with AcuCort and have great expectations for the launch of Zeqmelit on the Nordic markets.”
About Unimedic Pharma
Unimedic Pharma is a Swedish specialist pharmaceutical company that today supplies the Nordics and Northern Europe with a wide range of medicines in several therapeutic areas. The business is divided into three main business areas: Registered specialist medicines, Licensed medicines, Contract manufacturing (CDMO). The company's head office is in Solna and the company is a wholly owned subsidiary of MedCap AB (publ), which is listed on Nasdaq Stockholm Mid Cap. Read more at: www.unimedicpharma.se.
About AcuCort AB (publ)
AcuCort has developed and commercializes Zeqmelit®, a new fast-dissolving oral film to be placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy and for the treatment of patients with covid-19 who need supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway and Finland. AcuCort (short name: ACUC) is listed on the Spotlight Stock Market. Please visit www.acucort.se.